AAPP 2023 industry supported symposia are scientific programs developed for educational purposes. All symposia at AAPP 2023 are designed for the psychiatric pharmacist and are included in participant registration fees. All symposia are in compliance with Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation and provide 1.5 contact hours of ACPE credit.
All industry events feature a meal or refreshment break served 15 minutes before the session start time in Centennial I.
Lunch will be served from 11:15-11:30 AM Eastern in Centennial I, immediately before the program.
Faculty
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences
Norton College of Medicine, State University of New York Upstate Medical University
Syracuse, NY
Chief Medical Officer
Neuroscience Education Institute
Carlsbad, CA
Learning Objectives
Overview
There have been tremendous advances recently in the options available for treating bipolar spectrum disorders. In this symposium, Dr. Andrew Cutler will explore some of those advances and strategies for implementing them into clinical practice. The latest evidence-based diagnostic guidelines and treatments for BPI and BPII will be deliberated and investigated. Novel agents and notable achievements in the treatment of disorders across the bipolar spectrum with potential applications from depression with mixed features to psychotic mania will also be discussed.
Supported by
This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies.
Breakfast will be served from 7:00-7:15 AM in Centennial I, immediately before the program.
Faculty
Jonathan M. Meyer, MD
Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego School of Medicine
La Jolla, CA
Learning Objectives
Overview
New treatments for schizophrenia are just around the corner and their pharmacological properties bring into question the etiology of schizophrenia. Novel antipsychotic therapies without D2 receptor activity have significant implications for care, and if approved, will represent the "third-generation" of antipsychotic medications. Join Dr. Jonathan Meyer for a compelling symposium that will cover these recent advancements in our understanding of schizophrenia and how novel pharmacotherapies that act upstream of the dopamine receptors may prove effective at addressing current treatment limitations.
Supported by
This activity is supported by an unrestricted educational grant from Sunovion and Otsuka America Pharmaceutical, Inc.
Lunch will be served from 11:15-11:30 AM Eastern in Centennial I, immediately before the program.
Faculty
Lisa W. Goldstone, PharmD, MS, BCPS, BCPP
Associate Professor of Clinical Pharmacy
Director of the Residency Programs
Titus Family Department of Clinical Pharmacy
USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Los Angeles, California
Learning Objectives
Overview
Schizophrenia is a mental disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions and requires continuous and effective long-term management to reduce symptoms, improve quality of life, and prevent relapses. While oral antipsychotics have proven to be efficacious for many patients, ongoing symptoms and relapse remain a problem due to nonadherence. Long-acting injectable (LAI) antipsychotics are an underutilized treatment alternative that, when administered early on, improve adherence and reduce/prevent relapses and hospitalizations. It is important that pharmacists are familiar with the substantial health and economic burdens associated with schizophrenia, including high rates of medication nonadherence and symptomatic relapses, to effectively identify patients who may be ideal candidates for LAI antipsychotics as well as counsel patients/caregivers about schizophrenia and possible treatments. This activity will discuss current guidelines and data on LAIs to enable pharmacists to make appropriate recommendations in the treatment of patients with schizophrenia.
Supported by
Breakfast will be served from 7:00-7:15 AM in Centennial I, immediately before the program.
Faculty
Stephen R. Saklad, PharmD, BCPP
Clinical Professor and Director of Psychiatric Pharmacy
Division of Pharmacotherapy
The University of Texas at Austin College of Pharmacy,
UT Health San Antonio Pharmacotherapy Education and Research Center
San Antonio, Texas
Learning Objectives
Overview
Bipolar disorder (BD) is a lifelong mental health condition that is characterized by recurrent episodes of emotional manic or depressive symptoms. There are numerous traditional therapies used to treat acute mania and depressive episodes. Because of the complexities surrounding these treatment regimens, low treatment response, and adverse effects experienced with the medications, nonadherence is common amongst patients with BD. With nonadherence being such a substantial concern, pharmacists can play an integral role in ensuring that hesitations and expectations are addressed at the initiation of therapy to improve the patient’s understanding and attitude toward necessary medications. This activity will cover the challenges associated with BD, treatment strategies, recent treatment advancements, investigational therapies, and the impact pharmaceutical interventions can have on disease outcomes. With greater understanding of the clinical burden, stigma, and adherence barriers associated with BD, pharmacists will be equipped to help better serve and manage patients.
Supported by
This activity is supported by an educational grant from Intra-Cellular Therapies, Inc.